New Parkinson's drug passes first safety check in small trial
NCT ID NCT06659562
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 33 times
Summary
This early-stage study tested a new drug, HER-096, in 32 people to see if it is safe and how the body processes it. First, healthy volunteers received a single injection. Then, people with Parkinson's disease received multiple injections over four weeks. The main goal was to check for side effects, not to measure if the drug improves symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE, IDIOPATHIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Research Services Turku - CRST Oy
Turku, Finland, Finland
Conditions
Explore the condition pages connected to this study.